ESMO 2017 | The promise of PARP inhibitors and their emerging role in ovarian cancer
Jonathan Ledermann, BSc, MD, FRCP, from University College London, London, UK, tells us how the three most promising PARP inhibitors; olaparib, niraparib and rucaparib might fit into the treatment landscape in ovarian cancer. He discusses the similarities between the 3 agents and his hopes for approvals across Europe. Dr Ledermann is excited about the results we are seeing and looks forward to the results of further trials, including those testing PARP inhibitors with other classes of drug, such as immunotherapy. Recorded at the ESMO 2017 Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up